GLP-1 Drug Pricing Guide: Best Prices as of May 2026
May 2026 GLP-1 pricing update: Wegovy HD 7.2 mg, Foundayo telehealth channels, Wegovy pill ramp, 503B June 29 deadline, Medicare Bridge July 1 launch.
The May 2026 GLP-1 pricing picture looks superficially similar to April but has shifted in three structurally meaningful ways.
First, the higher-dose tier is now established. Wegovy HD (semaglutide 7.2 mg), approved by the FDA in March 2026 and launched April 7, is shipping at $399/month self-pay and as low as $25/month for many commercially insured patients via the savings offer — pricing that sits between the standard Wegovy 2.4 mg and the next-generation incretins. Lilly's Foundayo (orforglipron) hit its fourth commercial week with 7,335 prescriptions per Citi's May 8 IQVIA note, with telehealth platforms accounting for roughly 35% of launch volume that the IQVIA retail tracker misses.
Second, the compounded-GLP-1 channel is closing. The FDA's April 30 proposal to strike semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list opened a 60-day comment window that closes June 29. After final rulemaking, large-scale 503B compounding effectively ends. The 503A pathway remains until the July 23-24 PCAC meeting, but the trajectory is clear — most patients currently paying $159-$349/month for compounded versions will need to migrate to branded supply.
Third, the Medicare GLP-1 Bridge launches July 1. Eligible Part D beneficiaries will pay $50/month for Wegovy, Zepbound, and potentially Foundayo through December 31, 2027. State Medicaid programs began joining May 1 and can opt in through January 1, 2027. This is the first concrete government-payer GLP-1 program with a defined pricing structure, though restricted to specific eligibility criteria.
The bottom-line price points for May 2026: commercially insured patients still pay as low as $25/mo with a savings card. Uninsured self-pay starts at $149/mo (Foundayo LillyDirect starter, Wegovy pill 1.5 mg) and runs to $499/mo (Wegovy injectable NovoCare). Medicare patients pay $50/mo through TrumpRx and (starting July 1) the GLP-1 Bridge. WAC list prices haven't moved meaningfully and remain disconnected from what anyone actually pays.
For the comprehensive April baseline, see GLP-1 Pricing: April 2026. For the Medicare program in detail, see Medicare GLP-1 Bridge Pricing 2026. For the Canada generic semaglutide story, see Generic Semaglutide Canada Pricing.
Wegovy HD (Semaglutide 7.2 mg, for Obesity) — New Higher-Dose Tier
Novo Nordisk's higher-dose injectable semaglutide for chronic weight management, FDA-approved March 2026 and launched April 7, 2026. The STEP UP trial reported 21% mean weight loss at 72 weeks and 27.7% in early responders (May 12 ECO 2026 analysis). Requires four-plus weeks of tolerability on standard Wegovy 2.4 mg before stepping up.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,349/mo | NovoCare |
| NovoCare Self-Pay (7.2 mg) | $399/mo | Novo Nordisk PR |
| Commercial Insurance + Savings Card | As low as $25/mo | Wegovy.com |
| Medicare GLP-1 Bridge | $50/mo copay | CMS |
Foundayo (Orforglipron) — Launch Tracker and Channel Mix Update
Eli Lilly's oral GLP-1 pill, FDA-approved April 1, 2026. The May 8 Citi IQVIA tracker showed 7,335 Week 4 prescriptions; Lilly executives have cited 20,000 total patients with telehealth platforms accounting for ~35% of launch volume not captured in retail-only IQVIA data. Citi modeled $146M Q2 revenue and $1.6B for full-year 2026.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $649/mo | GoodRx |
| LillyDirect Vials (Starting Dose) | $149/mo | Eli Lilly PR |
| LillyDirect (Maintenance Dose) | ~$349/mo | Drugs.com |
| Foundayo via Telehealth (Range) | $199-$399/mo | Fierce Pharma / Citi note |
| TrumpRx (Oral GLP-1) | $150/mo | AMCP |
| Medicare Part D (Bridge) | $50/mo copay | KFF |
| Commercial Insurance + Savings Card | As low as $25/mo | Eli Lilly PR |
Wegovy Pill (Oral Semaglutide 25 mg) — Q1 2026 Ramp
Novo Nordisk's oral semaglutide tablet for weight management, launched January 5, 2026. Q1 2026 sales hit DKK 2.26B (~$354M) on roughly 1.3 million Q1 prescriptions, beating analyst consensus 2x. Now ~65% of all new US GLP-1 prescriptions per Novo CEO Mike Doustdar's May Q1 commentary. International launches confirmed for H2 2026 with EU approval expected before year-end.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,349/mo | NovoCare |
| Self-Pay (Starter Doses) | $149/mo | NovoCare Price Guide |
| Self-Pay (Maintenance Doses) | $299/mo | NovoCare Price Guide |
| GoodRx Self-Pay (Ozempic Pill, Diabetes Indication) | $149/$199/$299/mo | GoodRx |
| TrumpRx (Oral GLP-1) | $150/mo | AMCP |
| WeightWatchers Med+ Channel | From $149/mo | WeightWatchers |
Compounded Semaglutide & Tirzepatide — 60-Day Sunset Window
The FDA's April 30 proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list opened a 60-day comment window closing June 29, 2026. After final rulemaking, large-scale compounding through 503B outsourcing facilities effectively ends. The 503A pathway through licensed pharmacies remains until the July 23-24 PCAC meeting. Telehealth platforms running on compounded supply (Hims & Hers, LifeMD, others) have been migrating to branded distribution since Q1 2026.
| Channel | Price | Source |
|---|---|---|
| Compounded Semaglutide (Starting Dose) | $159-$199/mo | Newswire / Trinity Meds |
| Compounded Tirzepatide | $229-$349/mo | HealthFactsJournal |
| FDA 503B Bulks List Removal (Proposed) | Effective post-June 29, 2026 | Foley & Lardner |
| Hims & Hers Branded Pivot | Branded Wegovy/Ozempic via Novo partnership | Hims Investor Relations |
Foundayo International Launches — UAE Launch May 12
Eli Lilly's Foundayo reached UAE pharmacies May 12 in Abu Dhabi after the April Dubai launch. The Emirates Drug Establishment first approved Foundayo on April 3, making the UAE the second country globally to register the once-daily oral GLP-1 pill after the US. Health Canada generic semaglutide approvals (Dr. Reddy's April 28, Apotex May 1) make Canada the first G7 country with two approved Ozempic generics; Sandoz commercial launch Q3 2026.
| Channel | Price | Source |
|---|---|---|
| Foundayo UAE (0.8 mg) | AED 773/mo (~$210 USD) | The National (UAE) |
| Foundayo UAE (17.2 mg) | AED 1,599/mo (~$435 USD) | Gulf News |
| Wegovy Pill International (EU Approval Pending) | Expected H2 2026 launch | CNBC |
| Health Canada Generic Semaglutide (Apotex) | Q3 2026 commercial launch (Sandoz) | Health Canada |
Medicare GLP-1 Bridge & TrumpRx — July 1 Launch Confirmed
The Medicare GLP-1 Bridge program launches July 1, 2026 with $50/mo patient copay and ~$245/mo Medicare-negotiated price. Coverage runs through December 31, 2027. State Medicaid programs began joining May 1, 2026 and can opt in through January 1, 2027. Eligibility requires BMI 30+ with comorbidity, or BMI 27+ with pre-diabetes or established cardiovascular disease. The April 22 cancellation of the broader BALANCE pilot constrained the program scope.
Lilly Indiana Manufacturing — $4.5B Lebanon Investment for Supply
Eli Lilly committed an additional $4.5B to two Lebanon Indiana LEAP District sites for Foundayo and retatrutide production on May 6, 2026, opening Lilly Lebanon Advanced Therapies — the company's first dedicated genetic medicine manufacturing facility — the same day. Total Indiana capital commitments since 2020 now exceed $21B. The investment provides domestic Foundayo + retatrutide supply chain independent of peptide-CDMO bottlenecks. Doesn't change patient prices but signals Lilly's commitment to maintaining supply through the GLP-1 demand wave.
| Channel | Price | Source |
|---|---|---|
| Lilly Indiana Capital Commitment (Cumulative) | $21B+ since 2020 | Eli Lilly IR |
| May 6, 2026 Additional Commitment | $4.5B across two LEAP District sites | Eli Lilly IR |